VANI Vivani Medical

Vivani Medical: SLIM-1 Phase 1 initiation on track for mid-2026

The company confirmed that the SLIM-1 Phase 1 study of NPM-139 (semaglutide implant) remains on schedule for initiation in mid-2026 in Australia. Top-line data are now guided for end-2026, and a Phase 2 study is planned for 2027 pending positive results and an IND filing.

Vivani Medical plans Phase 1 study of NPM-139 semaglutide implant

Vivani will advance NPM-139, its miniature semaglutide implant, into a Phase 1 feasibility study in Australia starting mid-2026. The decision follows positive LIBERATE-1 first-in-human data and new preclinical results showing sustained semaglutide exposure and >20% sham-adjusted weight loss for a full year after a single administration. Cash from recent financings supports operations into mid-2027, covering the projected Phase 1 readout by year-end 2026.